Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.25 USD | -2.84% | -5.71% | -57.02% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.56 for the 2024 fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-57.02% | 340M | C+ | ||
-8.49% | 175B | C+ | ||
-1.08% | 107B | C | ||
-7.69% | 65.05B | A | ||
+2.81% | 50.76B | B- | ||
+6.66% | 43.14B | B- | ||
+5.93% | 41.46B | B+ | ||
+18.48% | 30.69B | B | ||
+13.37% | 25.39B | A- | ||
-5.39% | 23.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.